Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

214 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The prediction of early progressive disease in patients with hepatocellular carcinoma receiving atezolizumab plus bevacizumab.
Takeuchi Y, Nouso K, Fujioka SI, Kariyama K, Kobashi H, Uematsu S, Moriya A, Hagihara H, Takabatake H, Nakamura S, Yabushita K, Kikuchi T, Oyama A, Adachi T, Wada N, Onishi H, Shiraha H, Takaki A. Takeuchi Y, et al. Among authors: moriya a. Cancer Med. 2023 Sep;12(17):17559-17568. doi: 10.1002/cam4.6369. Epub 2023 Aug 3. Cancer Med. 2023. PMID: 37537956 Free PMC article.
Long-term monitoring of platelet count, as a non-invasive marker of hepatic fibrosis progression and/or regression in patients with chronic hepatitis C after interferon therapy.
Taniguchi H, Iwasaki Y, Fujiwara A, Sakaguchi K, Moriya A, Yu PC, Takaki A, Fujioka S, Shimomura H, Shiratori Y. Taniguchi H, et al. Among authors: moriya a. J Gastroenterol Hepatol. 2006 Jan;21(1 Pt 2):281-7. doi: 10.1111/j.1440-1746.2006.04201.x. J Gastroenterol Hepatol. 2006. PMID: 16460487
Intrahepatic mRNA levels of type I interferon receptor and interferon-stimulated genes in genotype 1b chronic hepatitis C. Association between IFNAR1 mRNA level and sustained response to interferon therapy.
Taniguchi H, Iwasaki Y, Takahashi A, Shimomura H, Moriya A, Yu PC, Umeoka F, Fujioka S, Koide N, Shiratori Y. Taniguchi H, et al. Among authors: moriya a. Intervirology. 2007;50(1):32-9. doi: 10.1159/000096310. Epub 2006 Nov 24. Intervirology. 2007. PMID: 17164555
Long-term outcome and hepatocellular carcinoma development in chronic hepatitis B or cirrhosis patients after nucleoside analog treatment with entecavir or lamivudine.
Kobashi H, Miyake Y, Ikeda F, Yasunaka T, Nishino K, Moriya A, Kubota J, Nakamura S, Takaki A, Nouso K, Yamada G, Yamamoto K. Kobashi H, et al. Among authors: moriya a. Hepatol Res. 2011 May;41(5):405-16. doi: 10.1111/j.1872-034X.2011.00785.x. Epub 2011 Mar 21. Hepatol Res. 2011. PMID: 21435126
Pro-angiogenic cytokines for prediction of outcomes in patients with advanced hepatocellular carcinoma.
Miyahara K, Nouso K, Morimoto Y, Takeuchi Y, Hagihara H, Kuwaki K, Onishi H, Ikeda F, Miyake Y, Nakamura S, Shiraha H, Takaki A, Honda M, Kaneko S, Sato T, Sato S, Obi S, Iwadou S, Kobayashi Y, Takaguchi K, Kariyama K, Takuma Y, Takabatake H, Yamamoto K; Okayama Liver Cancer Group. Miyahara K, et al. Br J Cancer. 2013 Oct 15;109(8):2072-8. doi: 10.1038/bjc.2013.554. Epub 2013 Sep 17. Br J Cancer. 2013. PMID: 24045661 Free PMC article.
Entecavir Reduces Hepatocarcinogenesis in Chronic Hepatitis B Patients.
Yasunaka T, Ikeda F, Wada N, Morimoto Y, Fujioka S, Toshimori J, Kobashi H, Kariyama K, Morimoto Y, Takayama H, Seno T, Takaguchi K, Moriya A, Miyatake H, Okamoto R, Yabushita K, Takaki A, Yamamoto K. Yasunaka T, et al. Among authors: moriya a. Acta Med Okayama. 2016;70(1):1-12. doi: 10.18926/AMO/53996. Acta Med Okayama. 2016. PMID: 26899604 Free article.
Real-world virological efficacy and safety of elbasvir and grazoprevir in patients with chronic hepatitis C virus genotype 1 infection in Japan.
Toyoda H, Atsukawa M, Takaguchi K, Senoh T, Michitaka K, Hiraoka A, Fujioka S, Kondo C, Okubo T, Uojima H, Tada T, Yoneyama H, Watanabe T, Asano T, Ishikawa T, Tamai H, Abe H, Kato K, Tsuji K, Ogawa C, Shimada N, Iio E, Deguchi A, Itobayashi E, Mikami S, Moriya A, Okubo H, Tani J, Tsubota A, Tanaka Y, Masaki T, Iwakiri K, Kumada T. Toyoda H, et al. Among authors: moriya a. J Gastroenterol. 2018 Dec;53(12):1276-1284. doi: 10.1007/s00535-018-1473-z. Epub 2018 May 8. J Gastroenterol. 2018. PMID: 29740665
Mixed HCV Infection of Genotype 1B and Other Genotypes Influences Non-response during Daclatasvir + Asunaprevir Combination Therapy.
Wada N, Ikeda F, Mori C, Takaguchi K, Fujioka SI, Kobashi H, Morimoto Y, Kariyama K, Sakaguchi K, Hashimoto N, Moriya A, Kawaguchi M, Miyatake H, Hagihara H, Kubota J, Takayama H, Takeuchi Y, Yasunaka T, Takaki A, Iwasaki Y, Okada H. Wada N, et al. Among authors: moriya a. Acta Med Okayama. 2018 Aug;72(4):401-406. doi: 10.18926/AMO/56178. Acta Med Okayama. 2018. PMID: 30140089 Free article.
The Efficacy and Safety of Steroids for Preventing Postembolization Syndrome after Transcatheter Arterial Chemoembolization of Hepatocellular Carcinoma.
Kuwaki K, Nouso K, Miyashita M, Makino Y, Hagihara H, Moriya A, Adachi T, Wada N, Yasunaka Y, Yasunaka T, Takeuchi Y, Onishi H, Nakamura S, Ikeda F, Shiraha H, Takaki A, Okada H. Kuwaki K, et al. Among authors: moriya a. Acta Med Okayama. 2019 Aug;73(4):333-339. doi: 10.18926/AMO/56935. Acta Med Okayama. 2019. PMID: 31439956 Free article. Clinical Trial.
214 results